Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Augusta Eduafo, DO, Leland Metheny, III, MD, James Driscoll, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139856

Published: 2020

Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142197

Published: 2020

Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140042

Published: 2020

Journal Articles

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Ehsan Malek, MD, Jeries Kort, MD, Gi-Ming Wang, PhD, Paolo F Caimi, MD, Kirsten M Boughan, DO, Stanton L. Gerson, MD, Brenda W. Cooper, MD, Molly M Gallogly, MDPhD, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Curtis Tatsuoka, PhD, James Driscoll

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-139733

Published: 2020

Journal Articles

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Paolo Caimi, MD, Deepa Jagadeesh, MDMPH, Kirsten Marie Boughan, DO, Robert M. Dean, MD, Brenda Cooper, MD, Brad Pohlman, MD, Molly M Gallogly, MDPhD, Sarah L. Ondrejka, DO, Erika Moore, MD, Kwadwo Asare Oduro, MDPhD, Eric D. Hsi, MD, Marcos de Lima, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 397.

https://doi.org/10.1182/blood-2018-99-115587

Published: 2018

Journal Articles

Leukocyte Subtypes As Predictors for Venous Thromboembolism in Diffuse Large B-Cell Lymphoma

Jahnavi Gollamudi, MD, Gouri Dharmavaram, Petra Martin, MD, Kirsten Marie Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Lalitha V. Nayak, MD, Paolo Caimi, MD

Blood (2018) 132 (Supplement 1): 495.

https://doi.org/10.1182/blood-2018-99-114225

Published: 2018

Journal Articles

Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Madison Keenan, Kirsten Marie Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MDPhD, Stanton L. Gerson, MD, Hillard M Lazarus, MD, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir, MPH, Benjamin K. Tomlinson, MD, Erika Moore, MD, Kwadwo Asare Oduro, MD PhD, Rose Beck, MD PhD, Howard Meyerson, MD, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2018) 132 (Supplement 1): 575.

https://doi.org/10.1182/blood-2018-99-117587

Published: 2018

Journal Articles

Small Molecule Activators of Protein Phosphatase 2A (SMAPs) Cause c-Myc Degradation and Tumor Growth Suppression in Preclinical Models of Lymphoid Malignancies

Molly M Gallogly, MDPhD, Eric Yuan, MPhil, Sahar Mazhar, BA, Caroline Farrington, BA, Goutham Narla, MD PhD

Blood (2017) 130 (Supplement 1): 2819.

https://doi.org/10.1182/blood.V130.Suppl_1.2819.2819

Published: 2017

Journal Articles

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Molly M Gallogly, MDPhD, Ben K. Tomlinson, MD, Pam Bunner, MT, CCRC, Paolo Caimi, MD, Michael Craig, MD, Marcos de Lima, MD, Stanton L. Gerson, MD, Donna Kane, RN, MSN, Hillard M Lazarus, MD, Mark J. Levis, MD, Ehsan Malek, MD, Jane A. Little, MD, Crystal Street, MT, CCRC, Willem J. van Heeckeren, MD PhD, William Tse, MD, Brenda W. Cooper, MD

Blood (2017) 130 (Supplement 1): 1332.

https://doi.org/10.1182/blood.V130.Suppl_1.1332.1332

Published: 2017

NARROW

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Leukocyte Subtypes As Predictors for Venous Thromboembolism in Diffuse Large B-Cell Lymphoma

Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Small Molecule Activators of Protein Phosphatase 2A (SMAPs) Cause c-Myc Degradation and Tumor Growth Suppression in Preclinical Models of Lymphoid Malignancies

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only